Although neratinib has been shown to improve outcomes for patients with HER2+ BC, neratinib‐induced diarrhea can present challenges and must be actively managed with dose escalation and/or antidiarrheal prophylaxis, as well as dose reductions and dose holds. The gene discussed is ERBB2; the disease is breast cancer.